Are all weight loss drugs injections? Not any more

The biggest misconception: GLP-1 means injection

Ask almost anyone what a weight loss medicine looks like right now and they'll say a pen you inject once a week. That assumption is understandable, the headlines over the last three years have been almost entirely about injectable semaglutide and tirzepatide. A question our prescribers hear most weeks is some version of: "I'd like to try one of these medicines but I'm scared of needles, is there any other way?"

Until recently, the honest answer was limited. Now it isn't. On 11 June 2026 the MHRA approved the Wegovy tablet (oral semaglutide co-formulated with an absorption enhancer) making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. That changes the practical answer to this question in a meaningful way. Injectable formats are still the most established, with the longest track record and the largest clinical datasets, but they are no longer the only licensed route.

The other non-injection option (orlistat, a capsule taken three times daily with meals) works entirely differently, blocking roughly a third of dietary fat from being absorbed. It has been available in the UK for many years and does not involve any injection at all. A fuller comparison of non-injectable weight loss medicines covers both orlistat and the Wegovy tablet side by side if you want more detail on that end of the spectrum.

What the injectable medicines actually involve, and why many people find them manageable

Mounjaro (tirzepatide, made by Eli Lilly) and the Wegovy injection (semaglutide, made by Novo Nordisk) are both once-weekly subcutaneous injections delivered via pre-filled pens. Subcutaneous means into the fatty tissue just beneath the skin (the abdomen, thigh or upper arm) not into muscle or a vein. The needles are short and fine, and most people find the injection itself far less daunting in practice than they expected beforehand.

Both medicines work through gut-hormone pathways that reduce appetite and slow gastric emptying. Mounjaro activates two receptors (GIP and GLP-1), which is why it is sometimes described as a dual agonist; Wegovy acts on GLP-1 alone. In the SURMOUNT-1 trial, tirzepatide produced an average body-weight reduction of around 20–21% over 72 weeks at the highest dose, as published in the New England Journal of Medicine. The STEP 1 trial for semaglutide 2.4mg showed around 15% average reduction over 68 weeks. These are the figures most often quoted in discussions of how effective weight loss medicines can be, and they come from injectable versions.

That clinical weight behind the injectable options is worth keeping in mind when comparing formats. The Wegovy tablet trial (OASIS 4) reported around 13.6% average weight loss over 64 weeks, a meaningful result, though somewhat lower than the injectable data. Whether that trade-off makes sense for a given person is exactly the sort of thing a prescriber works through during a clinical consultation. If you want to understand what the weight loss injection drugs are and how they compare, our dedicated overview sets out the key differences between tirzepatide and semaglutide in plain terms.

The oral option: what the Wegovy tablet is and how it's taken

The Wegovy tablet contains semaglutide combined with SNAC, a compound that allows the medicine to be absorbed through the stomach lining. Without that absorption enhancer, oral semaglutide would be broken down before it could reach the bloodstream in meaningful quantities, which is why it took considerably longer to develop an effective oral formulation than an injectable one.

Taking the tablet correctly matters. It is taken once daily, first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120ml). You then wait at least 30 minutes before any food, any other drink including coffee, or any other oral medicine. The tablet is swallowed whole. The schedule starts at 1.5mg daily and titrates up through 4mg and 9mg to the 25mg maintenance dose, spending at least a month at each level, a slower titration than most people expect. One practical advantage is storage: unlike the injection pens, the tablets need no refrigeration, which makes them considerably easier to travel with.

It is also worth being clear about what the Wegovy tablet is not. Rybelsus (also oral semaglutide) is licensed for type 2 diabetes at 3mg, 7mg and 14mg doses. Those are different medicines for a different indication. The weight management tablet and the diabetes tablet are not interchangeable, and the dose strengths do not overlap. If you have seen Rybelsus mentioned and wondered whether it applies to you, our page covering non-injection weight loss drugs can help clarify how the injectable and oral options differ and where each sits within the treatment landscape.

For information on how private treatment is priced across formats, the weight loss treatment overview sets out what to expect. You can also find detail on weight loss drugs given by injection, including how they are supplied and administered through regulated UK services. The NHS medicines page for tirzepatide and the equivalent page for semaglutide are also useful references for understanding what each medicine does from a regulatory standpoint.

If you are weighing up formats and want a prescriber's view on what suits your circumstances, start a free consultation and a GPhC-registered prescriber at our pharmacy will review your answers the same day.